DUSP1 modulators(dual specificity phosphatase 1 modulators), MFN2 modulators(mitofusin 2 modulators), TMBIM6 modulators(transmembrane BAX inhibitor motif containing 6 modulators)

+ [1]

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [3]

Active Indication

Heart FailurePeriodontitisBrain Ischemia+ [5]

Inactive Indication-

Originator Organization

Chinese Medical Sciences China Academy

Active Organization

Chinese Medical Sciences China AcademyThe Attached Hospital to Hainan Medical College

The First Affiliated Hospital of Zhengzhou University

+ [5]

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with Ginsenoside Rb1

100 Translational Medicine associated with Ginsenoside Rb1

100 Patents (Medical) associated with Ginsenoside Rb1

Literatures (Medical) associated with Ginsenoside Rb1

01 Apr 2025·Biomaterials Advances

Biodegradable copper-containing mesoporous microspheres loaded with ginsenoside Rb1 for infarcted heart repair

Article

Author: Jin, Qishu ; Wang, Ruqi ; Xu, Jinfeng ; Qiu, Yuanzheng ; Chen, Dongmin ; Sheng, Xiaosheng ; Yang, Chen ; Que, Yumei ; Li, Huili ; Chang, Jiang ; Su, Lefeng

The current unavailability of efficient myocardial repair therapies constitutes a significant bottleneck in the clinical management of myocardial infarction (MI). Ginsenoside Rb1 (GRb1) has emerged as a compound with potential benefits in safeguarding myocardial cells and facilitating the regeneration of myocardial tissue. However, its efficacy in treating MI-related ischemic conditions is hampered by its low bioavailability and inadequate angiogenic properties. In this study, the therapeutic potential of GRb1 is enhanced by a mesoporous basic copper carbonate (BCC) microsphere due to its excellent drug delivery capability and steady angiogenic degradation products (copper ions, Cu²⁺). The cell experiments revealed that GRb1 and Cu²⁺ could generate synergistic impacts on anti-cardiomyocyte apoptosis and endothelial cell angiogenesis, while a mouse model of MI illustrated that GRb1 loaded BCC (BCC@GRb1) could significantly enhance cardiac function, diminish the area of infarction and myocardial hypertrophy, reduce cardiomyocyte apoptosis, and augment vascularization within myocardial tissue. This investigation is pioneering in demonstrating the beneficial outcomes of combining drugs with bioactive carriers in myocardial regeneration and introduces a novel, precisely engineered drug delivery system as a potential therapeutic strategy for ischemic heart disease.

01 Feb 2025·Pharmacological Research

Ginsenosides Rg1, Rb1 and rare ginsenosides: Promising candidate agents for Parkinson's disease and Alzheimer's disease and network pharmacology analysis

Review

Author: Yuan, Liangjie ; Zhang, Zhixin ; Qiao, Yifan ; Liu, Jia ; Jiang, Mingchun ; Sheng, Xinhao ; Wang, Jinpeng ; Chi, Jiaxin

Ginseng has been commonly used as a traditional Chinese medicine in Asian countries for thousands of years. Ginsenosides are the main pharmacologically active ingredients isolated from ginseng and have neuroprotective effects in the treatment of neurodegenerative disorders, such as Parkinson's disease (PD) and Alzheimer's disease (AD). To summarise and investigate the protective roles of ginsenosides and their underlying mechanisms in PD and AD, we used ''Ginsenoside", ''Parkinson's disease", ''Alzheimer's disease", ''anti-inflammatory", ''antioxidant", and ''apoptosis" as keywords to search and extract relevant literature information from scientific databases such as Elsevier, PubMed, and Google Scholar databases. In particular, we used network pharmacology to identify the potential targets of ginsenosides Rg1 and Rb1 in PD and AD. By analysing the existing research advances and network pharmacology results, we found that the neuroprotective effects of ginsenosides, primarily mediated through anti-inflammation, anti-apoptosis and anti-oxidative stress, etc, may be associated with the PI3K/Akt, BDNF/TrkB, MAPKs, NF-κB, Nrf2 and Wnt/β-catenin signalling pathways. This review systematically summarises the different roles and mechanisms of ginsenosides Rg1, Rb1, and rare ginsenosides in PD and AD and provides new strategies for the treatment of neurodegenerative disorders. Network pharmacology provides a new research paradigm for the treatment of PD and AD using Rg1 and Rb1.

01 Feb 2025·International Journal of Biological Macromolecules

Immobilization of snailase and β-glucosidase on L-aspartic acid-modified magnetic amorphous ZIF for efficiently and sustainably producing ginsenoside compound K

Article

Author: Wu, Zhansheng ; Yang, Bolong ; Tian, Duoduo ; Cui, Chunxiao ; Gao, Runzi ; Luo, Shuqi

Improving the catalytic efficiency and recyclability of immobilized enzyme remained a serious challenge in industrial applications. Enzyme immobilization in the amorphous zeolite imidazolate framework (aZIF) preserved high enzyme activity, but still faced separation difficulties and a low catalytic efficiency in practice. In this study, a one-pot co-precipitation method was used to form the enzyme-aZIF/magnetic nanoparticle (MNP) biocomposite by rapidly precipitating snailase (Sna) and β-glucosidase (β-G) with metal/ligand on MNP and modifying with L-aspartic acid (Asp). Thanks to Asp modification protecting the natural conformation of internal protein molecules and MNP stabilizing the conformation of active enzymes after immobilizing, Sna&β-G in the carrier had more stable conformations and higher catalytic efficiency than those in conventional ZIF-8, increasing the catalytic efficiency for converting ginsenoside Rb1 to rare ginsenoside compound K (CK) to 79.16 %. Moreover, while improving the stability of Sna&β-G, owing to the magnetism imparted by MNP, the immobilized enzyme maintained high enzyme activity and recovery after 7 cycles by rapid magnetic separation. The results provided guidance for developing immobilized Sna&β-G biocomposites with ideal catalytic efficiency and easy recovery to catalyze ginsenoside Rb1 to rare ginsenoside CK.

100 Deals associated with Ginsenoside Rb1

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure	Preclinical	CN	Chinese Medical Sciences China Academy	01 Sep 2024
Periodontitis	Preclinical	CN	Xi'an Jiaotong University	18 Aug 2024
Brain Ischemia	Preclinical	CN	Anhui University of Chinese Medicine	25 Jul 2024
Diabetic Cardiomyopathies	Preclinical	CN	Shanghai University of Traditional Chinese Medicine	01 Jul 2024
Cardiotoxicity drug-induced	Preclinical	CN	The First Affiliated Hospital of Zhengzhou University	01 May 2024
Myocardial injury	Preclinical	CN	Chengdu University of Traditional Chinese Medicine	01 May 2024
Squamous cell carcinoma of the oral cavity	Preclinical	CN	The Attached Hospital to Hainan Medical College	26 Mar 2024
Neoplasms	Preclinical	CN	Shandong University	22 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Ginsenoside Rb1

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation